Antibody reduces harmful brain amyloid plaques in Alzheimer's patients

01-Sep-2016 - Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer's disease. These protein deposits in the brain are a classic sign of Alzheimer's disease and contribute to the ...

Biogen Idec and Sobi Initiate Global Clinical Trials of Long-Lasting Hemophilia A and B Product Candidates in Children

09-Jul-2012 - Biogen Idec and Swedish Orphan Biovitrum announced the initiation of two global pediatric clinical trials of the companies' long-lasting recombinant Factor VIII and Factor IX Fc fusion proteins (rFVIIIFc and rFIXFc) in hemophilia A and B.rFVIIIFc and rFIXFc are fully-recombinant clotting factors ...

Swedish Orphan Biovitrum's Hemophilia A Therapy Receives European Commission Orphan Drug Designation

24-Sep-2010 - Swedish Orphan Biovitrum announced that the European Commission has granted orphan drug designation to its long-lasting, fully-recombinant Factor FVIII Fc fusion protein (rFVIIIFc), which is partnered with Biogen Idec. It was recently announced that the companies plan to advance the rFVIIIFc ...

Biogen Idec and Swedish Orphan Biovitrum Decide to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial

13-Jul-2010 - Biogen Idec and Swedish Orphan Biovitrum announced that they plan to advance the companies' long-lasting, fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) into a registrational clinical trial in people with hemophilia A. The decision to advance the program is based on promising data ...

Biovitrum Advances Novel Factor VIII Long-Acting Hemophilia A Therapy into Clinical Trials

17-Dec-2009 - Biovitrum AB announced that the first patient was dosed in a phase I/IIa study of its long-acting fully-recombinant Factor VIII Fc fusion (rFVIIIFc) protein. The phase I/IIa open-label study will assess the safety, tolerability and pharmacokinetics of rFVIIIFc in severe, previously-treated, ...

Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial

21-Oct-2009 - Biogen Idec and Biovitrum AB announced that they plan to advance the companies' long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients. The decision to advance the program is based on promising data from a Phase I/IIa ...

Biogen Idec Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis

13-Jul-2009 - Biogen Idec announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). Biogen Idec is currently enrolling patients in a global Phase III study evaluating the efficacy and safety of either ...

UCB and Biogen Idec discontinue Phase II clinical trial of CDP323

Preliminary interim efficacy analysis showed no clinically relevant benefit for patients

01-Jul-2009 - UCB and Biogen Idec announced the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo ...

Dyax Announces Expansion of Antibody Discovery Collaboration with Biogen Idec

09-Feb-2009 - Dyax Corp. announced that they have expanded their antibody funded research and library license agreement with Biogen Idec to include the discovery of additional antibody products identified using Dyax’s proprietary drug discovery technology, phage display. Dyax has utilized phage display to ...

Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA

27-Nov-2008 - Biovitrum AB and Syntonix Pharmaceuticals, Inc., a subsidiary of Biogen Idec announced that the company's FIXFc compound for the control and prevention of hemorrhagic episodes in patients with hemophilia B has received an orphan-drug designation from the US Food and Drug Administration (FDA). ...